Tokushima University / Educator and Researcher Directory --- Mitsui, Yasuhiro

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Koichi Okamoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Kouzou Yoshikawa, Masahiro Sogabe, Yasushi Sato, Joji Shunto, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)., Gastric Cancer, Vol.27, No.3, 635-640, 2024. (Summary) A 44-year-old woman with gastric cancer (GC) and fundic gland polyposis (FGPs) was referred to our hospital for further diagnosis and treatment. She successfully underwent eradication therapy for Helicobacter pylori (HP) 6 years ago, but did not exhibit FGPs at that time. When she underwent an esophagogastroduodenoscopy 2, 4, and 5 years after the eradication of HP, her imaging results revealed the existence of FGPs which gradually increased in her gastric fundus and body. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was suspected and a mutational analysis was performed, revealing an APC promoter 1B variant c.-191T > C. A robotic total gastrectomy with lymphadenectomy was performed. Histopathological analysis of the surgical specimens revealed GC with no lymph node metastasis. GAPPS is characterized by GC and FGPs. However, our case shows different gastric phenotypes that are dependent on the status of HP infection. (Keyword) Female / Humans / Adult / Stomach Neoplasms / Helicobacter pylori / Adenocarcinoma / Helicobacter Infections / Polyps / Adenomatous Polyps (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-024-01473-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38407681 ● Search Scopus @ Elsevier (PMID): 38407681 ● Search Scopus @ Elsevier (DOI): 10.1007/s10120-024-01473-x (DOI: 10.1007/s10120-024-01473-x, PubMed: 38407681)
2.	Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama : Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series., Clinical Journal of Gastroenterology, Vol.Online ahead of print., 2023. (Summary) Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the benefits and side effects of immune checkpoint inhibitor (ICI) therapy and the relationship between side effects and prognosis remain unclear. Herein, we describe the clinical presentation of five patients with AM treated with ICI as well as their relationship to the treatment course and the development of immune-related adverse events (irAEs). Three patients received sequential or concurrent administrations of nivolumab and ipilimumab, one received nivolumab alone, and one received ipilimumab alone. The response rate (RR) and disease control rate (DCR) were 40% and 80%, respectively. Pituitary and hepatic dysfunctions were the most common irAEs observed (40% each), followed by thyroid, diarrhea, and renal dysfunctions (20% each). The RR was 67% in patients with irAEs while no response was observed in patients without irAEs. DCR was 100% and 50% in patients with and without irAEs, respectively. Overall survival was 34 months in irAE and 8.75 months in non-irAE cases, with a longer survival trend in irAE cases. ICI therapy was effective and well-tolerated by AM patients, with potentially better outcomes for those who experienced irAEs compared to those who did not. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-023-01849-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37632658 ● Summary page in Scopus @ Elsevier: 2-s2.0-85169147432 (DOI: 10.1007/s12328-023-01849-z, PubMed: 37632658, Elsevier: Scopus)
3.	Koichi Okamoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Yasushi Sato and Tetsuji Takayama : "Tip-in underwater endoscopic mucosal resection" without submucosal injection for superficial nonampullary duodenal adenomas., Endoscopy, Vol.55, No.S1, E965-E966, 2023. (Keyword) Humans / Endoscopic Mucosal Resection / Duodenal Neoplasms / Duodenum / Injections (Tokushima University Institutional Repository) ● Metadata: 118931 (Link to Publication Site) ● Publication site (DOI): 10.1055/a-2134-9080 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37604451 ● Summary page in Scopus @ Elsevier: 2-s2.0-85168452995 (Tokushima University Institutional Repository: 118931, DOI: 10.1055/a-2134-9080, PubMed: 37604451, Elsevier: Scopus)
4.	Taku Takahashi, Yasushi Sato, Takanori Kashihara, Yoshihiro Miyata, Yasuteru Fujino, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yasuhiko Nishioka and Tetsuji Takayama : Nintedanib-Induced Gastric Antral Vascular Ectasia in Patients with Idiopathic Pulmonary Fibrosis., ACG Case Reports Journal, Vol.10, e01107, 2023. (Link to Publication Site) ● Publication site (DOI): 10.14309/crj.0000000000001107 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.14309/crj.0000000000001107 (DOI: 10.14309/crj.0000000000001107)
5.	Yasushi Sato, Yasuyuki Okada, Yasuteru Fujino, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Hironori Tanaka, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Masahiro Sogabe and Tetsuji Takayama : Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 154-159, 2023. (Summary) In Japan, cancer genome profiling (CGP) for cancer patients without standard treatment has been covered by public insurance since June 2019. This study analyzed data of 122 patients with gastrointestinal tumors who underwent CGP to clarify cancer genome medicine's current status and possible problems at the Tokushima University Hospital. The major types of cancer included pancreatic (n=30), colorectal (n=25), biliary tract (n=15), gastric (n=11), and hepatocellular carcinoma (n=8). CGP tests included F1CDx in 70 patients (57%), F1LCDx in 36 (30%), TSO500 in 14 (11%), and NCC Oncopanel in 2 (2%). Actionable gene alterations were identified in 72 patients (59%), but only 5 patients (4%) were treated for pancreatic (n=1), colorectal (n=3), and small bowel cancers (n=1). The main reasons for not receiving genotype-matched therapy included the lack of appropriate drugs or clinical trials that matched the actionable gene alterations (n=40) and the inability to participate in clinical trials (n=10). There is still not a sufficient number of patients receiving genotype-matched treatment for gastrointestinal cancers. To promote cancer genome medicine in regional areas, attempts to improve access to genotype-matched therapies are required, as well as to promote the development of new molecular-targeted drugs and clinical trials for these drugs. J. Med. Invest. 70 : 154-159, February, 2023. (Keyword) Humans / Gastrointestinal Neoplasms / Neoplasms / Colorectal Neoplasms / Genomics / Hospitals / Japan (Tokushima University Institutional Repository) ● Metadata: 118346 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.154 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164713 ● Search Scopus @ Elsevier (PMID): 37164713 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.154 (Tokushima University Institutional Repository: 118346, DOI: 10.2152/jmi.70.154, PubMed: 37164713)
6.	Megumi Yamasaki, Yasushi Sato, Koichi Okamoto, Akira Fukuya, Tomoyuki Kawaguchi, Kazuyoshi Noda, Kaizo Kagemoto, Yasuhiro Mitsui, Hiroshi Miyamoto and Tetsuji Takayama : Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S1 (DCS) induction chemotherapy followed by chemoradiation., Clinical Journal of Gastroenterology, Vol.16, No.2, 180-186, 2022. (Summary) Anal squamous cell carcinoma (ASCC) is an uncommon tumor. However, its incidence is increasing worldwide. Surgical resection of locally advanced cases requires permanent anal prosthesis. Thus, chemoradiotherapy (CRT) is preferred as the first-line treatment; however, high local recurrence rate remains an issue. Here, we describe two cases of locally advanced ASCC treated with docetaxel + cisplatin + S-1 (DCS) followed by CRT with S-1 that showed complete response. The two patients, aged 69 and 65 years, were diagnosed with ASCC (cStage IIIB) at our hospital. Due to extensive lymph node metastases, the patients were treated with triple induction chemotherapy (DCS) followed by CRT with S-1. Positron emission tomography/computed tomography performed six months after starting the treatment showed disappearance of tumors, indicating a complete response. The patients continued to receive S-1 for one year and achieved relapse-free long-term survival since the completion of treatment. Therefore, induction chemotherapy with DCS, prior to CRT with S-1 may benefit patients with locally advanced ASCC. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-022-01736-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36409453 ● Search Scopus @ Elsevier (PMID): 36409453 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-022-01736-z (DOI: 10.1007/s12328-022-01736-z, PubMed: 36409453)
7.	hironori wada, Yasuteru Fujino, Kaizo Kagemoto, Yoshifumi Kida, Yasuyuki Okada, Yasuhiro Mitsui, Koichi Okamoto, Yasushi Sato, Yoshimi Bando, Hiroshi Miyamoto and Tetsuji Takayama : Gastric cancer genome profiling reveals HER2 false-negative status and informs a successful trastuzumab treatment strategy, The Japanese Journal of Gastro-enterology, Vol.119, No.10, 937-945, 2022. (Summary) Intratumoral HER2 heterogeneity is a well-described gastric cancer feature and may explain many false-negative results related to this oncogene. An 81-year-old man was diagnosed at our hospital with stage IV gastric cancer with multiple lymph node metastases. Immunohistochemistry (IHC) analysis indicated that the primary tumor was HER2-negative. After a chemotherapy course, we submitted a pretreatment biopsy specimen for comprehensive cancer genome profiling (CGP) to determine the last-line therapy. This revealed HER2 amplification. The specimen was reevaluated using fluorescence in situ hybridization and IHC with deeper-cut specimens, which confirmed that the tumor was indeed HER2-positive. Therefore, the patient was treated with chemotherapy plus trastuzumab, which elicited tumor shrinkage and conferred long-term survival. Our current data underscore the CGP importance, which can provide more accurate tumor profilings and inform subsequent treatment decisions. (Keyword) がん遺伝子パネル検査 / Trastuzumab / HER2陽性胃癌 (Link to Publication Site) ● Publication site (DOI): 10.11405/nisshoshi.119.937 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36216544 ● CiNii @ National Institute of Informatics (CRID): 1390293710918867840 ● Search Scopus @ Elsevier (PMID): 36216544 ● Search Scopus @ Elsevier (DOI): 10.11405/nisshoshi.119.937 (DOI: 10.11405/nisshoshi.119.937, PubMed: 36216544, CiNii: 1390293710918867840)
8.	Yasuhiro Mitsui, Mai Yagi, Sho Muraki, Tomomi Matsuura, Yoshimi Bando, Shota Fujimoto, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masataka Sata and Tetsuji Takayama : Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood., Internal Medicine, Vol.61, No.10, 1491-1495, 2022. (Tokushima University Institutional Repository) ● Metadata: 118012 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8313-21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34670901 ● Search Scopus @ Elsevier (PMID): 34670901 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.8313-21 (Tokushima University Institutional Repository: 118012, DOI: 10.2169/internalmedicine.8313-21, PubMed: 34670901)
9.	Fumika Nakamura, Yasushi Sato, Koichi Okamoto, Yasuteru Fujino, Yasuhiro Mitsui, kaizo kagemoto, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Tomoko Sonoda, Koichi Tsuneyama and Tetsuji Takayama : Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome., Journal of Gastroenterology, Vol.57, No.4, 286-299, 2022. (Summary) Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis. (Keyword) Adenoma / Carcinoma / Colonic Polyps / Colorectal Neoplasms / Humans / Intestinal Polyposis / Microsatellite Instability / Mutation / Proto-Oncogene Proteins B-raf / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117614 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-022-01858-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35194694 ● Search Scopus @ Elsevier (PMID): 35194694 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01858-8 (Tokushima University Institutional Repository: 117614, DOI: 10.1007/s00535-022-01858-8, PubMed: 35194694)
10.	Kumiko Tanaka, Yasushi Sato, Hideki Ishikawa, Naoki Muguruma, Satoshi Teramae, Yoji Takeuchi, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda, Naoki Omiya, Michihiro Mutoh and Tetsuji Takayama : Small Intestinal Involvement and Genotype-Phenotype Correlation in Familial Adenomatous Polyposis., Techniques and Innovations in Gastrointestinal Endoscopy, Vol.24, No.1, 26-34, 2022. (Tokushima University Institutional Repository) ● Metadata: 116979 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tige.2021.10.001 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1360861291391377024 ● Summary page in Scopus @ Elsevier: 2-s2.0-85119353922 (Tokushima University Institutional Repository: 116979, DOI: 10.1016/j.tige.2021.10.001, CiNii: 1360861291391377024, Elsevier: Scopus)
11.	Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Hiroyuki Ueda, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Yasushi Sato, Rika Aoki, Joji Shunto, Yoshimi Bando and Tetsuji Takayama : Clinicopathological characteristics of early gastric cancer associated with autoimmune gastritis., JGH Open, Vol.5, No.10, 1210-1215, 2021. (Tokushima University Institutional Repository) ● Metadata: 116931 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12656 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34622010 ● Summary page in Scopus @ Elsevier: 2-s2.0-85114915216 (Tokushima University Institutional Repository: 116931, DOI: 10.1002/jgh3.12656, PubMed: 34622010, Elsevier: Scopus)
12.	Sayo Takahashi, Koichi Okamoto, Toshihito Tanahashi, Shota Fujimoto, Tadahiko Nakagawa, Masahiro Bando, beibei ma, Tomoyuki Kawaguchi, Yasuteru Fujino, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Yoshimi Bando, Toshiro Sato, Takahiro Fujimori and Tetsuji Takayama : S100P expression via DNA hypomethylation promotes cell growth in the sessile serrated adenoma/polyp-cancer sequence., Digestion, Vol.102, No.5, 789-802, 2021. (Summary) Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor lesion of colon cancer. Although the relevance of DNA hypermethylation in the SSA/P-cancer sequence is well documented, the role of DNA hypomethylation is unknown. We investigated the biological relevance of DNA hypomethylation in the SSA/P-cancer sequence by using 3-dimensional organoids of SSA/P. We first analyzed hypomethylated genes using datasets from our previous DNA methylation array analysis on 7 SSA/P and 2 cancer in SSA/P specimens. Expression levels of hypomethylated genes in SSA/P specimens were determined by RT-PCR and immunohistochemistry. We established 3-dimensional SSA/P organoids and performed knockdown experiments using a lentiviral shRNA vector. DNA hypomethylation at CpG sites of the gene was quantitated by MassARRAY analysis. The mean number of hypomethylated genes in SSA/P and cancer in SSA/P was 41.6 ± 27.5 and 214 ± 19.8, respectively, showing a stepwise increment in hypomethylation during the SSA/P-cancer sequence. S100P, S100α2, PKP3, and MUC2 were most commonly hypomethylated in SSA/P specimens. The mRNA and protein expression levels of S100P, S100α2, and MUC2 were significantly elevated in SSA/P compared with normal colon tissues, as revealed by RT-PCR and immunohistochemistry, respectively. Among these, mRNA and protein levels were highest for S100P. Knockdown of the S100P gene using a lentiviral shRNA vector in 3-dimensional SSA/P organoids inhibited cell growth by >50% (p < 0.01). The mean diameter of SSA/P organoids with S100P gene knockdown was significantly smaller compared with control organoids. MassARRAY analysis of DNA hypomethylation in the S100P gene revealed significant hypomethylation at specific CpG sites in intron 1, exon 1, and the 5'-flanking promoter region. These results suggest that DNA hypomethylation, including S100P hypomethylation, is supposedly associated with the SSA/P-cancer sequence. S100P overexpression via DNA hypomethylation plays an important role in promoting cell growth in the SSA/P-cancer sequence. (Tokushima University Institutional Repository) ● Metadata: 115966 (Link to Publication Site) ● Publication site (DOI): 10.1159/000512575 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33395688 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099095900 (Tokushima University Institutional Repository: 115966, DOI: 10.1159/000512575, PubMed: 33395688, Elsevier: Scopus)
13.	藤井祥平, Fumika Nakamura, Yasushi Sato, 岸和弘, Sumiko Yoshida, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE) との関連性についての検討, Shikoku Acta Medica, Vol.76, No.3-4, 173-178, 2020. (Summary) Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients. (Keyword) Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050004953486029824 (CiNii: 1050004953486029824)
14.	Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama : Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma., Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020. (Summary) The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC. (Tokushima University Institutional Repository) ● Metadata: 115325 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-020-01705-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196 (Tokushima University Institutional Repository: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus)
15.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Yasuteru Fujino, Yasuhiro Mitsui, Akihiro Hirao, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Harumi Kagiwada, Masashi Kitazawa, Kazuhiro Fukui, Ktsuhisa Horimoto and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array., Oncotarget, Vol.11, No.26, 2531-2542, 2020. (Summary) The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group ( < 0.05). Patients with better liver functional reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC of LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR. (Tokushima University Institutional Repository) ● Metadata: 116246 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27640 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32655838 ● Search Scopus @ Elsevier (PMID): 32655838 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27640 (Tokushima University Institutional Repository: 116246, DOI: 10.18632/oncotarget.27640, PubMed: 32655838)
16.	Tadahiko Nakagawa, Yasushi Sato, Toshihito Tanahashi, Yasuhiro Mitsui, Yoshifumi Kida, Yasuteru Fujino, Misato Hirata, Shinji Kitamura, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama : JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8., Gastric Cancer, Vol.23, No.3, 426-436, 2020. (Summary) Jumonji domain-containing protein 2A (JMJD2A) of the JMJD2 family of histone lysine demethylases has been implicated in tumorigenesis. However, its expression and role in gastric cancer (GC) drug resistance remain unknown. Here, we investigated the role of JMJD2A in GC chemotherapeutic susceptibility and its clinical relevance in GC. We selected 12 relevant genes from previously identified gene signatures that can predict GC susceptibility to docetaxel, cisplatin, and S-1 (DCS) therapy. Each gene was knocked down using siRNA in GC cell lines, and cell viability assays were performed. JMJD2A expression in GC cell lines and tissues was assessed using qRT-PCR and immunohistochemistry, respectively. A JMJD2A downstream target related to drug susceptibility was examined using whole-gene expression array and immunoprecipitation. Among the 12 candidate genes, down-regulation of JMJD2A showed the maximum effect on GC susceptibility to anti-cancer drugs and increased the IC values for 5-FU, cisplatin, and docetaxel 15.3-, 2.7-, and 4.0-fold, respectively. JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients. A whole-gene expression array of JMJD2A-knockdown GC cells demonstrated a significant decrease in the expression of pro-apoptotic coiled-coil domain containing 8 (CCDC8), a downstream target of JMJD2A. Direct interaction between CCDC8 and JMJD2A was verified using immunoprecipitation. CCDC8 inhibition restored drug resistance to docetaxel, cisplatin, and S-1. Our results indicate that JMJD2A is a novel epigenetic factor affecting GC chemotherapeutic susceptibility, and JMJD2A/CCDC8 is a potential GC therapeutic target. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-019-01024-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31677131 ● Summary page in Scopus @ Elsevier: 2-s2.0-85074813194 (DOI: 10.1007/s10120-019-01024-9, PubMed: 31677131, Elsevier: Scopus)
17.	Yasuhiro Mitsui, Reiko Yokoyama, Shota Fujimoto, Kaizoh Kagemoto, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Yoshimi Bando, Hidetaka Eguchi, Yasushi Okazaki, Hideyuki Ishida and Tetsuji Takayama : First report of an Asian family with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) revealed with the germline mutation of the APC exon 1B promoter region., Gastric Cancer, Vol.21, No.6, 1058-1063, 2018. (Summary) A 48-year-old Japanese female with left hypochondralgia presented at our hospital. Esophagogastroduodenoscopy (EGD) revealed gastric cancers and carpeting fundic gland polyposis (FGPs) without Helicobacter pylori infection. Computed tomography showed multiple liver metastases. Total colonoscopy revealed a colonic tubular adenoma but not polyposis. She was diagnosed as having advanced gastric cancer with liver metastasis and received chemotherapy. Her mother had died from gastric cancer, and her elderly brother and niece had FGPs as revealed by EGD. Thus, the pedigree was diagnosed as gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). Germline mutation analysis exhibited a point mutation in exon1B of the APC gene (c.-191T > C). Adenocarcinoma showed a gastric mucinous phenotype and was positive for a somatic mutation of p53, suggesting that p53 mutation may play a role in FGPs carcinogenesis. This is the first family with GAPPS in Asia in whom germline mutation of APC exon 1B has been detected. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-018-0855-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29968043 ● Summary page in Scopus @ Elsevier: 2-s2.0-85049558259 (DOI: 10.1007/s10120-018-0855-5, PubMed: 29968043, Elsevier: Scopus)
18.	Daisaku Fujimoto, Naoki Muguruma, Koichi Okamoto, Yasuteru Fujino, Kaizoh Kagemoto, Yasuyuki Okada, Yoshifumi Takaoka, Yasuhiro Mitsui, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda and Tetsuji Takayama : Linked color imaging enhances endoscopic detection of sessile serrated adenoma/polyps., Endoscopy International Open, Vol.6, No.3, E322-E334, 2017. (Summary) Although new image-enhanced endoscopy (IEE) technologies such as blue laser imaging (BLI), BLI-bright, and linked color imaging (LCI) have been developed, their utility for the detection of sessile serrated adenoma/polyps (SSA/Ps) is still unclear. This study aimed to evaluate the utility of BLI, BLI-bright, and LCI for SSA/P detection in still image examinations and in a prospective randomized controlled trial (RCT). A group of 6 expert and non-expert endoscopists read 200 endoscopic still images containing SSA/P lesions using white light image (WLI), BLI, BLI-bright, and LCI. Color differences were calculated using the color space method. A prospective RCT of tandem colonoscopy with WLI and LCI was performed. Patients with SSA/P and those with a history of SSA/P that had been endoscopically removed were enrolled and randomly allocated to WLI-LCI or LCI-WLI groups. Additional endoscopic detection rates for SSA/P were compared between the 2 groups. LCI showed the highest SSA/P detection rate among the 4 modes for both expert and non-expert endoscopists. The detection rate with LCI for the 6 expert endoscopists (mean 98.3 ± standard deviation 2.0 %) was significantly higher than that with WLI (86.7 ± 6.0 %, < 0.01). Likewise, the detection rate with LCI for the 6 non-expert endoscopists (92.3 ± 2.9 %) was significantly higher than that with WLI (72.7 ± 11.5 %, < 0.01). The color difference of SSA/P with LCI was the highest among the 4 modes, and was significantly higher than with WLI (median 15.9, (interquartile range 13.7 - 20.6) vs. 10.2, (7.6 - 14.2); < 0.0001). In the RCT, a total of 44 patients (WLI-LCI 22 vs. LCI-WLI 22) underwent colonoscopy. The additional detection rate for SSA/P in the second inspection in the WLI-LCI group (21.6 %, 8/37) was significantly higher than in the LCI-WLI group (3.2 %, 1/31; = 0.02). The small, flat, non-mucus and isochromatic SSA/Ps in the transverse colon were detected more frequently in the second inspection with LCI. LCI was the most sensitive mode for SSA/P detection among WLI, BLI, BLI-bright, and LCI in the still image examinations. Our RCT strongly suggests that LCI is superior to conventional WLI for SSA/P detection during colonoscopy. UMIN000017599. (Tokushima University Institutional Repository) ● Metadata: 111442 (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0043-124469 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29527554 ● Search Scopus @ Elsevier (PMID): 29527554 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0043-124469 (Tokushima University Institutional Repository: 111442, DOI: 10.1055/s-0043-124469, PubMed: 29527554)
19.	Naoki Muguruma, Koichi Okamoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Shota Fujimoto, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Jun Higashijima, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka, Tetsuo Nagano, Makoto Shibutani and Tetsuji Takayama : Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1., Scientific Reports, Vol.7, No.1, 6536, 2017. (Summary) Aberrant crypt foci (ACF), the earliest precursor lesion of colorectal cancers (CRCs), are a good surrogate marker for CRC risk stratification and chemoprevention. However, the conventional ACF detection method with dye-spraying by magnifying colonoscopy is labor- and skill-intensive. We sought to identify rat and human ACF using a fluorescent imaging technique that targets a molecule specific for ACF. We found that glutathione S-transferase (GST) P1-1 was overexpressed in ACF tissues in a screening experiment. We then synthesized the fluorogenic probe, DNAT-Me, which is fluorescently quenched but is activated by GSTP1-1. A CRC cell line incubated with DNAT-Me showed strong fluorescence in the cytosol. Fluorescence intensities correlated significantly with GST activities in cancer cell lines. When we sprayed DNAT-Me onto colorectal mucosa excised from azoxymethane-treated rats and surgically resected from CRC patients, ACF with strong fluorescent signals were clearly observed. The ACF number determined by postoperative DNAT-Me imaging was almost identical to that determined by preoperative methylene blue staining. The signal-to-noise ratio for ACF in DNAT-Me images was significantly higher than that in methylene blue staining. Thus, we sensitively visualized ACF on rat and human colorectal mucosa by using a GST-activated fluorogenic probe without dye-spraying and magnifying colonoscopy. (Tokushima University Institutional Repository) ● Metadata: 112373 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-06857-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28747791 ● Search Scopus @ Elsevier (PMID): 28747791 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-017-06857-x (Tokushima University Institutional Repository: 112373, DOI: 10.1038/s41598-017-06857-x, PubMed: 28747791)
20.	Shinji Kitamura, Toshihito Tanahashi, Eriko Aoyagi, Tadahiko Nakagawa, Koichi Okamoto, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Kazuhito Rokutan, Naoki Muguruma and Tetsuji Takayama : Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes., Oncology, Vol.93, No.2, 127-135, 2017. (Summary) The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer who received DCS as a first-line therapy. Laser capture microdissection was performed, and total cellular RNA was extracted from each microdissected sample. Whole-gene expression was analyzed by microarray, and the difference in mRNA expression observed with the microarrays was confirmed by quantitative real-time PCR. Immunohistochemical staining was performed using clinical tissue sections obtained by endoscopic biopsy. Eleven patients were identified as early responders and 8 patients as nonresponders to DCS therapy. Twenty-nine genes showed significant differences in relative expression ratios between tumor and normal tissues. A classifier set of 29 genes had high accuracy (94.7%) for distinguishing gene expression between 11 early responders and 8 nonresponders. Decreasing the size of the classifier set to 4 genes (PDGFB, PCGF3, CISH, and ANXA5) increased the accuracy to 100%. Expression levels by real-time PCR for validation were well correlated with those 4 genes in microarrays. The genes identified may serve as efficient biomarkers for personalized cancer-targeted therapy. (Tokushima University Institutional Repository) ● Metadata: 111015 (Link to Publication Site) ● Publication site (DOI): 10.1159/000464329 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28511180 ● Summary page in Scopus @ Elsevier: 2-s2.0-85019884830 (Tokushima University Institutional Repository: 111015, DOI: 10.1159/000464329, PubMed: 28511180, Elsevier: Scopus)
21.	Koichi Okamoto, Naoki Muguruma, Kaizo Kagemoto, Yasuhiro Mitsui, Daisaku Fujimoto, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama : Efficacy of hybrid endoscopic submucosal dissection (ESD) as a rescue treatment in difficult colorectal ESD cases., Digestive Endoscopy, Vol.29, No.suppl.2, 45-52, 2017. (Summary) Endoscopic submucosal dissection (ESD), which provides a higher en bloc resection rate than conventional endoscopic mucosal resection (EMR), is considered to be a useful treatment option for large colorectal tumors. However, colorectal ESD is not widely used because of its technical difficulty, risk of complications and time required. To overcome these drawbacks, a simpler modified technique, ESD with snaring (hybrid ESD), has been developed. The aim of the present study was to retrospectively compare the safety and efficacy of hybrid ESD and conventional ESD for colorectal tumors. Between September 2008 and June 2016, ESD was carried out on 137 lesions and hybrid ESD on 27 lesions. All hybrid ESD cases were carried out as a rescue treatment in difficult ESD cases. We retrospectively investigated procedure time, and the rates of en bloc resection, perforation, bleeding, and local recurrence. In the hybrid ESD group, procedure time was shorter compared with the ESD group (108 ± 59.5 min vs 122 ± 72.2 min), but the en bloc resection rate was lower (66.7% vs 94.2%). However, there were no significant differences in procedure time, or in rates of en bloc resection, perforation and bleeding between the two groups. Local recurrence did not develop in any of our cases. Hybrid ESD as a rescue treatment in difficult ESD cases may be less effective for en bloc resection of large colorectal tumors. Indication for hybrid ESD may be limited to scheduled treatment from the outset and emergency cases with patients who present unstable vital signs during ESD. (Link to Publication Site) ● Publication site (DOI): 10.1111/den.12863 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28425649 ● Search Scopus @ Elsevier (PMID): 28425649 ● Search Scopus @ Elsevier (DOI): 10.1111/den.12863 (DOI: 10.1111/den.12863, PubMed: 28425649)
22.	Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Masanori Takehara, kaizo Kagamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, Sayo Matsumoto, Toshi Takaoka, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Masahiro Sogabe, Naoki Muguruma, Toshiya Okahisa, Yasuhiro Sato, Tamotsu Sagawa, Koji Fujikawa, Yasushi Sato, Hitoshi Ikushima and Tetsuji Takayama : A Phase I/II Study of Fixed-dose-rate Gemcitabine and S-1 with Concurrent Radiotherapy for Locally Advanced Pancreatic Cancer, Cancer Chemotherapy and Pharmacology, Vol.76, No.3, 615-620, 2015. (Summary) This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently. Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73%, respectively. The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC. (Tokushima University Institutional Repository) ● Metadata: 110046 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-015-2835-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26220846 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939568942 (Tokushima University Institutional Repository: 110046, DOI: 10.1007/s00280-015-2835-3, PubMed: 26220846, Elsevier: Scopus)
23.	Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Yasuteru Fujino, Yasuhiro Mitsui, Yoshihumi Takaoka, Tetsuo Kimura, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users, Medicine, Vol.94, No.26, e1047, 2015. (Summary) Antiplatelet drugs are widely used for the prevention of cardiovascular disease and cerebral vascular disorders. Although there have been several studies on gastroduodenal mucosal injury with gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug users (including low-dose aspirin (LDA)), there have been few reports on the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users. This study was a cross-sectional study elucidating the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Subjects were 186 asymptomatic Japanese antiplatelet drug users who underwent a regular health checkup. Subjects were divided into those with and without gastroduodenal mucosal injury endoscopically, and the association between gastroduodenal mucosal injury and other data in asymptomatic antiplatelet drug users was investigated.The prevalence of males and drinkers were significantly higher in subjects with gastroduodenal mucosal injury than in those without. In addition, the prevalence of proton pump inhibitor (PPI) users was significantly lower in subjects with gastroduodenal mucosal injury than in subjects without gastroduodenal mucosal injury. Logistic regression analysis showed PPI (odds ratios: 0.116; 95% confidence intervals: 0.021-0.638; P < 0.05) was a significant predictor of a decreased prevalence of gastroduodenal mucosal injury and closed-type (C-type) atrophy (3.172; 1.322-7.609; P < 0.01) was a significant predictor of an increased prevalence of severe gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Gender and lifestyle, such as drinking, may have an impact on risk of gastroduodenal mucosal injury in asymptomatic subjects taking antiplatelet drugs. Although PPI is a significant predictor of a decreased prevalence of gastroduodenal mucosal injury, including in asymptomatic antiplatelet drug users, status of gastric atrophy should also be considered against severe gastroduodenal mucosal injury. (Keyword) Adult / Aged / Aged, 80 and over / Endoscopy, Gastrointestinal / Female / Gastric Mucosa / Humans / Male / Middle Aged / Platelet Aggregation Inhibitors / Retrospective Studies / Stomach Diseases / Young Adult (Tokushima University Institutional Repository) ● Metadata: 115594 (Link to Publication Site) ● Publication site (DOI): 10.1097/MD.0000000000001047 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26131815 ● Summary page in Scopus @ Elsevier: 2-s2.0-84942531762 (Tokushima University Institutional Repository: 115594, DOI: 10.1097/MD.0000000000001047, PubMed: 26131815, Elsevier: Scopus)
24.	Yasuhiro Mitsui, Yasushi Sato, Hiroshi Miyamoto, Yasuteru Fujino, Toshi Takaoka, Jinsei Miyoshi, Miwako Kagawa, Hiroyuki Ohnuma, Masahiro Hirakawa, Tomohiro Kubo, Takahiro Osuga, Tamotsu Sagawa, Yasuhiro Sato, Yasuo Takahashi, shinichi Katsuki, Toshinori Okuda, Rishu Takimoto, Masayoshi Kobune, Takayuki Nobuoka, Koichi Hirata, Junji Kato and Tetsuji Takayama : Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy., Cancer Chemotherapy and Pharmacology, Vol.76, No.2, 375-382, 2015. (Summary) We previously reported that a triplet combination of docetaxel, cisplatin, and S-1 (DCS) is active against metastatic gastric cancer with a very high response rate of 87.1 % in a phase II study. Recently, the efficacy of trastuzumab (T-mab) for the treatment of HER2-positive gastric cancer has been reported. Therefore, we investigated the feasibility and preliminary efficacy of DCS + T-mab (DCS-T) for unresectable HER2-positive metastatic gastric cancer. Patients received oral S-1 (40 mg/m(2) b.i.d.) on days 1-14, intravenous cisplatin (60 mg/m(2)), docetaxel (50 mg/m(2)), and T-mab (8 mg/kg in the first cycle and 6 mg/kg in the second cycle and thereafter) on day 8 every 3 weeks. The study included 16 patients: median age, 60 (34-76) years; males/females, 11:5; intestinal-type/diffuse-type histology, 11:5; and HER2 3+/2+(FISH+), 13:3. The completion rate until the third cycle was 87.5 % (14/16) (95 %CI 71.3-103.7 %). Adverse events of grade 3/4 severity during the first 3 cycles were: leukopenia/neutropenia, 50.0:75.0 %; febrile neutropenia, 12.5 %; diarrhea, 12.5 %; and stomatitis, 12.5 %. All of these side effects were manageable and well controlled. There were no treatment-related deaths. The overall response rate was 93.8 % (15/16), and the response rate in patients with measurable lesions was 100 % (15/15). The median cycle to response was only 1 (1-3 cycles). Non-curative factors disappeared in 56.3 % (9/16) of patients, and conversion surgery (R0 resection) was performed in all these cases. Pathological response rates in primary and metastatic lesions were 88.9 % (8/9) and 100 % (9/9), respectively. The median PFS and OS were not reached during the median follow-up time of 18.3 months ranged from 11.0 to 34.3 months. DCS-T was feasible in patients with unresectable HER2-positive metastatic gastric cancer. The observed response was very promising and warrants further investigation. UMIN000005603. (Keyword) Adult / Aged / Antibodies, Monoclonal, Humanized / Cisplatin / Drug Combinations / Feasibility Studies / Female / Humans / Male / Middle Aged / Neoplasm Metastasis / Oxonic Acid / Receptor, Epidermal Growth Factor / Stomach Neoplasms / Taxoids / Tegafur (Tokushima University Institutional Repository) ● Metadata: 109679 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-015-2807-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26099968 ● Summary page in Scopus @ Elsevier: 2-s2.0-84938207398 (Tokushima University Institutional Repository: 109679, DOI: 10.1007/s00280-015-2807-7, PubMed: 26099968, Elsevier: Scopus)
25.	Yasuhiro Mitsui, Kaizo Kagemoto, Tatsuzo Itagaki, Shuji Inoue, Keishi Naruse, Naoki Muguruma and Tetsuji Takayama : Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication., Clinical Journal of Gastroenterology, Vol.8, No.2, 71-88, 2015. (Summary) A 60-year-old male presented to our hospital for further investigation of abnormal findings on an upper gastrointestinal series. Esophagogastroduodenoscopy demonstrated atrophic gastritis and a submucosal tumor (SMT) at the anterior wall of the antrum. The patient was positive for serum anti-Helicobacter pylori (H. pylori) antibody and H. pylori eradication therapy was performed. Five months later, the SMT showed a remarkable morphological change in that an ulcer had developed on its apex, and partial gastrectomy was performed. Pathological examination suggested an inflammatory fibroid polyp (IFP), and genetic analysis revealed no mutation in the platelet-derived growth factor receptor alpha gene. This case suggests that H. pylori infection plays an important role in the etiology of IFPs. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-015-0557-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25733031 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939983772 (DOI: 10.1007/s12328-015-0557-z, PubMed: 25733031, Elsevier: Scopus)

Review, Commentary:

1.	Koichi Okamoto, Yasuhiro Mitsui, ta yoshimoto, shota fujimoto, t mitsuhashi, Hiroyuki Ueda, reiko yokoyama, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Fumika Nakamura, Yasushi Sato, 春藤譲治, Yoshimi Bando, 九嶋亮治 and Tetsuji Takayama : 遺伝性胃癌:病態解析と診断の進歩胃腺癌および近位胃ポリポーシス(GAPPS)を中心に., 胃と腸, Vol.58, No.12, 1589-1601, Dec. 2023.
2.	Yasushi Sato, Koichi Okamoto, Yoshifumi Kida, Yasuhiro Mitsui, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama : Overview of Chemotherapy for Gastric Cancer., Journal of Clinical Medicine, Vol.12, No.4, 1336, Feb. 2023. (Summary) Gastric cancer (GC) is one of the most clinically challenging cancers worldwide. Over the past few years, new molecular-targeted agents and immunotherapy have markedly improved GC prognosis. Human epidermal growth factor receptor 2 (HER2) expression is a key biomarker in first-line chemotherapy for unresectable advanced GC. Further, the addition of trastuzumab to cytotoxic chemotherapy has extended the overall survival of patients with HER2-positive advanced GC. In HER2-negative GC, the combination of nivolumab, an immune checkpoint inhibitor, and a cytotoxic agent has been demonstrated to prolong the overall survival of GC patients. Ramucirumab and trifluridine/tipiracil, which are second- and third-line treatments for GC, and trastuzumab deruxtecan, an antibody-drug conjugate for HER2-positive GC, have been introduced in clinics. New promising molecular-targeted agents are also being developed, and combination therapy comprising immunotherapy and molecular-targeted agents is expected. As the number of available drugs increases, it is important to understand the target biomarkers and drug characteristics and select the optimal therapy for each patient. For resectable disease, differences in the extent of standard lymphadenectomy between Eastern and Western countries have led to different standard treatments: perioperative (neoadjuvant) and adjuvant therapy. This review aimed to summarize recent advances in chemotherapy for advanced GC. (Tokushima University Institutional Repository) ● Metadata: 118894 (Link to Publication Site) ● Publication site (DOI): 10.3390/jcm12041336 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36835872 ● Search Scopus @ Elsevier (PMID): 36835872 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm12041336 (Tokushima University Institutional Repository: 118894, DOI: 10.3390/jcm12041336, PubMed: 36835872)

Proceeding of International Conference:

1.	Hiroyuki Ueda, Yasuhiro Mitsui, Makoto Takishita, Mitsuyasu Yano, Masanori Takehara, Akira Fukuya, Tomoyuki Kawaguchi, Kazuyoshi Noda, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathologial Analysis of Six Families with Gastric Adenocarcinoma and Proximal Polyposis of the stomach (GAPPS)., DDW2020, May 2020.
2.	Yasushi Sato, Kumiko Tanaka, Ishikawa Hideki, Satoshi Teramae, Fumika Nakamura, Yasuhiro Mitsui, Kagemoto Kaizo, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Ohmiya Naoki, Mutoh Michihiro and Tetsuji Takayama : Small- intestinal involvement in familial adenomatous polyposis: characteristics and genotype- phenotype correlation from a Japanese cohort study, DDW, May 2020.
3.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka and Tetsuji Takayama : Optical Molecular Imaging of Aberrant Crypt Foci in the Human Colon by Glutathione S-Transferase-Activated Fluorogenic Probe., Digestive Disease Week2017, Chicago, May 2017.
4.	Tomoyuki Kawaguchi, Naoki Muguruma, Koichi Okamoto, Kumiko Tanaka, Satoshi Teramae, Yasuhiro Mitsui, Yoshifumi Takaoka, Tatsunao Sueuchi, Takahiro Goji, Shinji Kitamura, Masako Kimura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : Assessment of small bowel capsule endoscopy and APC gene mutation in familial adenomatous polyposis., The First World Congress of Gastrointestinal Endoscopy, Hyderabad, Feb. 2017.
5.	Kaizo Kagemoto, Atsushi Inoue, Koichi Okamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Jinsei Miyoshi, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Proximal Aberrant Crypt Foci As Precursor Lesions of SSA/P-Cancer Sequence., Digestive Disease Week 2015, Washington, D.C., May 2015.

Proceeding of Domestic Conference:

1.	Hiroshi Miyamoto, Ayuka Mineda, Sawaka Yukishige, Soichiroh Sasa, Kei Daizumoto, Tomoya Fukawa, Yasuyuki Okada, Yasuhiro Mitsui, Koichi Okamoto, Yasushi Sato, Hiroyuki Morino and Tetsuji Takayama : Management of patients with presumed germline pathogenic variant from comprehensive genomic profiling tests., 日本人類遺伝学会第69回大会, Oct. 2024.
2.	Tomoyuki Kawaguchi, Koichi Okamoto, 三橋威志, 吉本貴則, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : <ワークショップ>Serrated polyposis syndromeの右側及び左側大腸病変の臨床病理学的差異の解析., 第110回日本消化器病学会総会, May 2024.
3.	takanori yoshimoto, Koichi Okamoto, Hiroyuki Ueda, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : <ワークショップ>Gastric adenocarcinoma and proximal polyposis of the stomach(GAPPS)の表現型とHelicobacter pylori(HP)感染症の関連についての検討., 第110回日本消化器病学会総会, May 2024.
4.	Hiroyuki Ueda, shota fujimoto, takano yoshimoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Koichi Okamoto, Yasushi Sato and Tetsuji Takayama : <ワークショップ>ヒト由来大腸癌オルガノイドを用いたTIMP1の右側大腸癌の予後不良因子としての検討., 第110回日本消化器病学会総会, May 2024.
5.	Koichi Okamoto, Motoko Sei, shota fujimoto, ta mitsuhashi, takanori yoshimoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : Serrated polyposis syndromeの右側及び左側大腸病変の臨床病理学的および分子生物学的解析, 第10回消化管ポリポーシス研究会, Jan. 2024.
6.	Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Yasuteru Fujino, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto and Tetsuji Takayama : 直腸悪性黒色腫に対する免疫チェックポイント阻害剤の効果予測因子としての irAE の意義., 第 61 回日本癌治療学会学術集会, Oct. 2023.
7.	Sayaka Ogimoto, Koichi Okamoto, Akira Takahashi, shota Fujimoto, Takanori Yoshimoto, Takeshi Mitsuhashi, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : 内視鏡による積極的大腸ポリープ摘除術を施行しているリンチ症候群の一例., 第5回がんゲノム医療時代におけるLynch症候群研究会学術集会, Aug. 2023.
8.	藤井祥平, Shinji Kitamura, Yasuhiro Mitsui, Yasushi Sato and Tetsuji Takayama : ボノプラザン長期投与後に胃ポリポーシスを発症し，胃上皮性腫瘍を認めた透析患者の1例., 第95回日本胃癌学会総会, Feb. 2023.
9.	Koichi Okamoto, Fumika Nakamura, 八木麻衣, 岡田明子, 藤井祥平, Takanori Yoshimoto, 横山怜子, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Yasushi Sato and Tetsuji Takayama : Serrated polyposis syndrome に合併した大腸腺腫の臨床病理学的特徴., 第98回大腸癌研究会学術集会, Jan. 2023.
10.	Kaizo Kagemoto, Fumika Nakamura, Koichi Okamoto, Takanori Yoshimoto, Tomoyuki Kawaguchi, 横山怜子, Yoshifumi Kida, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : 鋸歯状ポリポーシス症候群における大腸腫瘍の病理像と発癌機序についての解析., 第60回癌治療学会学術集会, Oct. 2022.
11.	Fumika Nakamura, Koichi Okamoto, kaizo kagemoto, 平田圭市郎, takanori yoshimoto, 横山怜子, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Kumiko Tanaka, Shinji Kitamura, Yasushi Sato and Tetsuji Takayama : Serrated polyposis syndromeにおける発癌リスクとその予防., 第29回日本がん予防学会総会, Jul. 2022.
12.	Yasuyuki Okada, Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : LAMC2 is a novel predictive biomarker for gemcitabine-based therapy in pancreatic ductal adenocarcinoma., 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
13.	上田浩之, Yasuhiro Mitsui, 滝下誠, 矢野充保, 福家慧, Tomoyuki Kawaguchi, Yoshifumi Kida, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathological analysis of six families with Gastric Adenocarcinoma and Proximal Polyposis of the Stomach(GAPPS)., 第18回日本臨床腫瘍学会学術集会, Feb. 2021.
14.	多田理香, 竹内彩郁薫, 山田青季, 井形直紀, Masaki Oono, Masami Shishibori, Masao Fuketa, Kenji Terada, Yoshifumi Kida, Tomoyuki Kawaguchi, Yasuhiro Mitsui, Tatsunao Sueuchi, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 睡眠中の腸蠕動音の解析に適した腸音図システムの試作開発., 第58回日本人工臓器学会大会, Nov. 2020.
15.	藤井祥平, Fumika Nakamura, Yasushi Sato, 岸和弘, Sumiko Yoshida, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : <第23回若手奨励賞>胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE)との関連性についての検討., Shikoku Acta Medica, Vol.76, No.3-4, 173-178, Aug. 2020. (Summary) Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients. (Keyword) Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050004953486029824 (CiNii: 1050004953486029824)
16.	Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
17.	Jinsei Miyoshi, 村山典聡, Satoshi Teramae, 宮本佳彦, Hironori Tanaka, 岡田泰行, Yasuhiro Mitsui, Yasuteru Fujino, Takahiro Tanaka, Kumiko Tanaka, 松村圭一郎, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 直腸NETのmicroRNA網羅的発現解析を用いた転移機序の解明と新規転移予測バイオマーカーの探索., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
18.	Yasuhiro Mitsui, 津保友香 and Tetsuji Takayama : 切除不能進行神経内分泌癌に対するIrinotecan+Cisplatin併用療法の臨床的有用性とサロゲートマーカーの検討., 第105回日本消化器病学会総会, May 2019.
19.	Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathological characteristics of Gastric adenocarcinoma with proximal polyposis of the stomach., 第91回日本胃癌学会総会, Mar. 2019.
20.	Yasuhiro Mitsui, Kumiko Tanaka, Satoshi Teramae, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Gastric adenocarcinoma with proximal polyposis of the stomach(GAPPS)家系における若年罹患者へのアプローチ., 第5回日本消化管ポリポーシス研究会(日本消化器病学会関連研究会), Jan. 2019.
21.	taro mizutani, ju nishioka, naoki igata, kazuhide iwasa, tetsuya honda, Tomoyuki Kawaguchi, Yasuhiro Mitsui, Jinsei Miyoshi, Tatsunao Sueuchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 携帯型小型腸音図システムの試作による腸蠕動音測定時間の最適化., 第56回日本人工臓器学会大会, Nov. 2018.
22.	和田浩典, Shinji Kitamura, Fumika Nakamura, Akira Fukuya, Masanori Takehara, Yasuyuki Okada, Yasuhiro Mitsui, Jinsei Miyoshi, Yasuteru Fujino, Kumiko Tanaka, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : CRT後咽頭狭窄を伴う表在型食道癌に対して細径内視鏡を用いたPDTが有効であった一例., 第56回日本癌治療学会学術集会, Oct. 2018.
23.	Satoshi Teramae, Kumiko Tanaka, 三橋威志, Yasuhiro Mitsui, Fumika Nakamura, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 新規APC遺伝子変異(C.1626+1G>A)を認めた家族性大腸腺腫症の一例., 第6回日本家族性大腸腺腫症研究会学術集会, Sep. 2018.
24.	Masanori Takehara, Yasushi Sato, 津保友香, Akira Fukuya, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Yasuteru Fujino, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 膵癌と脂肪細胞の相互作用はSAA1の発現を誘導することにより膵癌の浸潤を促進させる., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
25.	津保友香, Yasuhiro Mitsui, Akira Fukuya, Masanori Takehara, 岡田泰行, Jinsei Miyoshi, Yasuteru Fujino, Fumika Nakamura, Kumiko Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 切除不能進行神経内分泌癌に対するIrinotecan+Cisplatin併用療法の後方視的検討., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
26.	福家慧, Yasushi Sato, 佐川保, 高橋康雄, 大沼啓之, 濱口京子, 平川昌宏, 藤川幸司, Yasuteru Fujino, Yasuhiro Mitsui, 岡田泰行, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 切除不能進行胃癌に対するdocetaxel/ oxaliplatin/S-1(DOS)療法の第I相試験., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
27.	Yasuhiro Mitsui, Kumiko Tanaka, 寺前智史, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Gastric adenocarcinoma with proximal polyposis of the stomach(GAPPS)におけるAPC 遺伝子生殖細胞系列変異および臨床病理学的特徴., 第24回日本家族性腫瘍学会学術集会, Jun. 2018.
28.	Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma, Yasuhiro Mitsui, Shinji Kitamura, 藤本大策, Masahiro Sogabe, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : microRNA arrayを用いた大腸粘膜下層浸潤癌リンパ節転移に関わるバイオマーカーの同定及び機能解析, 第14回日本消化管学会総会学術集会, Feb. 2018.
29.	岡田泰行, Tetsuo Kimura, Koichi Okamoto, Fumika Nakamura, Yasuteru Fujino, Kumiko Tanaka, Jinsei Miyoshi, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 抗EGFR抗体薬治療におけるEarly tumor shrinkage(ETS)とEGFR内在化の関連について, 第88回大腸癌研究会, Jan. 2018.
30.	Yasuteru Fujino, 池田敬洋, Tetsu Tomonari, Yasuhiro Mitsui, 香川美和子, Momoko Sato, 仁木美也子, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Ipilimumab にて完全奏功が得られた転移性直腸悪性黒色腫の1例., 第 55 回日本癌治療学会学術集会,, Oct. 2017.
31.	高岡慶史, 影本開三, Yasuhiro Mitsui, Kumiko Tanaka, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masako Kimura, 仁木美也子, Hiroshi Miyamoto, Naoki Muguruma, 石川正志 and Tetsuji Takayama : 免疫チェックポイント阻害薬で加療した直腸肛門部悪性黒色腫の4例., 第55回日本癌治療学会学術集会, Oct. 2017.
32.	影本開三, Koichi Okamoto, 岡田泰行, 高岡慶史, Yasuhiro Mitsui, 藤本大策, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 画像強調内視鏡(IEE)によるヒト Aberrant crypt foci (ACF)の観察∼従来のメチレンブルー散布法と比較して∼., がん予防学術大会2017, Jun. 2017.
33.	藤本大策, 岡田怜子, 福家慧, 影本開三, Yasuhiro Mitsui, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 大腸サーベイランスにおけるSSA/P検出率の上昇を目指して―LCIの有用性の検討―, 第13回日本消化管学会総会学術集会, Feb. 2017.
34.	村山典聡, 寺前智史, Yasuhiro Mitsui, Yasuteru Fujino, Kumiko Tanaka, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndromeにおけるポリープ，大腸癌の性状と発癌機序の検討., 第13回日本消化管学会総会学術集会, Feb. 2017.
35.	Mayu Uyama, Masahiro Sogabe, 平田光里, Tadahiko Nakagawa, Akira Fukuya, Satoshi Teramae, Daisaku Fujimoto, Hironori Tanaka, Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Tetsuji Takayama, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Takahiro Emoto, Masatake Akutagawa, Rumi Katashima and Toshiya Okahisa : 模擬腹水による胸腹水濾過濃縮再静注法の教育体制の構築, 第37回日本アフェレシス学会学術大会, Nov. 2016.
36.	寺前智史, Kumiko Tanaka, Naoki Muguruma, 高岡慶史, 岡崎潤, 村山典聡, Tatsunao Sueuchi, Yasuhiro Mitsui, 藤本大策, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, 江副康正, 石川秀樹, 竹内洋司 and Tetsuji Takayama : 家族性大腸腺腫症における小腸病変についての検討, 第85回大腸癌研究会, Jul. 2016.
37.	武原正典, Hiroshi Miyamoto, 岡田泰行, Yasuhiro Mitsui, Yasuteru Fujino, Kumiko Tanaka, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, 仁木美也子, Masako Kimura, Naoki Muguruma, Toshiya Okahisa, Yoshimi Bando and Tetsuji Takayama : 化学療法により長期生存が得られた脾臓原発血管肉腫の一例, 第53回日本癌治療学会学術集会, Oct. 2015.
38.	影本開三, Tatsunao Sueuchi, Yasuhiro Mitsui, Kumiko Tanaka, 香川美和子, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masako Kimura, 仁木美也子, Hiroshi Miyamoto, Naoki Muguruma, 石川正志 and Tetsuji Takayama : Nivolumabにて加療した直腸肛門部悪性黒色腫の2例, 第53回日本癌治療学会学術集会, Oct. 2015.
39.	Jun Okazaki, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Masako Kimura, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : S-1/oxaliplatin/irinotecan (SOXIRI) for advanced unresectable pancreatic cancer : A dose-finding study, 第13回日本臨床腫瘍学会学術集会, Jul. 2015.
40.	Yasuhiro Mitsui, Naoki Muguruma, Kumiko Tanaka, 高岡慶史, Yasuteru Fujino, Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : 異なる胃病変を呈する家族性大腸腺腫症(FAP)の1家系, 第21回日本家族性腫瘍学会学術集会, Jun. 2015.
41.	岡崎潤, 福家慧, 影本開三, 高岡慶史, 宮本佳彦, 岡田泰行, 松本早代, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, 高岡遠, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : EUS-FNAで確定診断し得た小型退形成性膵管癌の1例., 第89回日本消化器内視鏡学会総会, May 2015.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Analysis of the carcinogenesis with GAPPS patients (Project/Area Number: 21K15551 )
Search by Researcher Number (80792366)

Assistant Professor : Mitsui, Yasuhiro

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)